Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Caroline Hasselbalch Riley

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Plos One|March 10, 2012
A highly sensitive quantitative real-time PCR assay for determination of mutant JAK2 exon 12 allele burdenLasse Kjær, Maj Westman, Caroline Hasselbalch Riley, et al.
Current Drug Targets|December 15, 2010
Interferon-alpha in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Status and perspectivesHans Carl Hasselbalch, Thomas Stauffer Larsen, Caroline Hasselbalch Riley, et al.
Oncoimmunology|September 20, 2018
Spontaneous T-cell responses against Arginase-1 in the chronic myeloproliferative neoplasms relative to disease stage and type of driver mutationMia Aaboe Jørgensen, Morten Orebo Holmström, Evelina Martinenaite, et al.
Oncoimmunology|June 7, 2018
Spontaneous T-cell responses against the immune check point programmed-death-ligand 1 (PD-L1) in patients with chronic myeloproliferative neoplasms correlate with disease stage and clinical responseMorten Orebo Holmström, Caroline Hasselbalch Riley, Vibe Skov, et al.
Ugeskrift for Laeger|March 6, 2024
Bue Ross Agner, Caroline Hasselbalch Riley, Søren Lykke Petersen, et al.
Diagnostic Microbiology and Infectious Disease|July 12, 2025
Borrelia afzelii-associated seronegative Lyme neuroborreliosis in an immunocompromised patientFreja Gustafsson, Ann-Brit Eg Hansen, Kurt Fuursted, et al.
Leukemia & Lymphoma|May 10, 2015
Minimal residual disease after long-term interferon-alpha2 treatment: a report on hematological, molecular and histomorphological response patterns in 10 patients with essential thrombocythemia and polycythemia veraCecilie Utke Rank, Ole Weis Bjerrum, Thomas Stauffer Larsen, et al.
Blood|June 29, 2011
Increase in circulating CD4⁺CD25⁺Foxp3⁺ T cells in patients with Philadelphia-negative chronic myeloproliferative neoplasms during treatment with IFN-αCaroline Hasselbalch Riley, Morten Krogh Jensen, Marie Klinge Brimnes, et al.
Leukemia & Lymphoma|December 3, 2016
The impact of interferon-alpha2 on HLA genes in patients with polycythemia vera and related neoplasmsVibe Skov, Caroline Hasselbalch Riley, Mads Thomassen, et al.
European Journal of Haematology|March 31, 2011
Whole-blood transcriptional profiling of interferon-inducible genes identifies highly upregulated IFI27 in primary myelofibrosisVibe Skov, Thomas Stauffer Larsen, Mads Thomassen, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Plos One|March 10, 2012
A highly sensitive quantitative real-time PCR assay for determination of mutant JAK2 exon 12 allele burdenLasse Kjær, Maj Westman, Caroline Hasselbalch Riley, et al.
Current Drug Targets|December 15, 2010
Interferon-alpha in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Status and perspectivesHans Carl Hasselbalch, Thomas Stauffer Larsen, Caroline Hasselbalch Riley, et al.
Oncoimmunology|September 20, 2018
Spontaneous T-cell responses against Arginase-1 in the chronic myeloproliferative neoplasms relative to disease stage and type of driver mutationMia Aaboe Jørgensen, Morten Orebo Holmström, Evelina Martinenaite, et al.
Oncoimmunology|June 7, 2018
Spontaneous T-cell responses against the immune check point programmed-death-ligand 1 (PD-L1) in patients with chronic myeloproliferative neoplasms correlate with disease stage and clinical responseMorten Orebo Holmström, Caroline Hasselbalch Riley, Vibe Skov, et al.
Ugeskrift for Laeger|March 6, 2024
Bue Ross Agner, Caroline Hasselbalch Riley, Søren Lykke Petersen, et al.
Diagnostic Microbiology and Infectious Disease|July 12, 2025
Borrelia afzelii-associated seronegative Lyme neuroborreliosis in an immunocompromised patientFreja Gustafsson, Ann-Brit Eg Hansen, Kurt Fuursted, et al.
Leukemia & Lymphoma|May 10, 2015
Minimal residual disease after long-term interferon-alpha2 treatment: a report on hematological, molecular and histomorphological response patterns in 10 patients with essential thrombocythemia and polycythemia veraCecilie Utke Rank, Ole Weis Bjerrum, Thomas Stauffer Larsen, et al.
Blood|June 29, 2011
Increase in circulating CD4⁺CD25⁺Foxp3⁺ T cells in patients with Philadelphia-negative chronic myeloproliferative neoplasms during treatment with IFN-αCaroline Hasselbalch Riley, Morten Krogh Jensen, Marie Klinge Brimnes, et al.
Leukemia & Lymphoma|December 3, 2016
The impact of interferon-alpha2 on HLA genes in patients with polycythemia vera and related neoplasmsVibe Skov, Caroline Hasselbalch Riley, Mads Thomassen, et al.
European Journal of Haematology|March 31, 2011
Whole-blood transcriptional profiling of interferon-inducible genes identifies highly upregulated IFI27 in primary myelofibrosisVibe Skov, Thomas Stauffer Larsen, Mads Thomassen, et al.
Pageof 3